Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.57 |
| ▸ | RPS6KA5 | O75582 | 9/20 | 0.53 |
| ▸ | AKT1 | P31749 | 14/20 | 0.52 |
| ▸ | RPS6KA1 | Q15418 | 12/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 13/20 | 0.51 |
| ▸ | AKT2 | P31751 | 4/20 | 0.49 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4295261 | 0.86 | AKT1 (0.61) | SLC2A1RPS6KA5AKT1RPS6KA1ROCK1 | |
| SCHEMBL4303867 | 0.85 | SLC2A1 (0.53) | SLC2A1RPS6KA5AKT1RPS6KA1ROCK1 | |
| SCHEMBL4301683 | 0.84 | SLC2A1 (0.57) | SLC2A1RPS6KA5AKT1RPS6KA1ROCK1 | |
| SCHEMBL4292488 | 0.84 | SLC2A1 (0.59) | SLC2A1RPS6KA5AKT1RPS6KA1ROCK1 | |
| SCHEMBL21350454 | 0.83 | AKT1 (0.73) | SLC2A1RPS6KA5AKT1RPS6KA1ROCK1 | |
| SCHEMBL4290330 | 0.83 | SLC2A1 (0.58) | SLC2A1RPS6KA5AKT1RPS6KA1ROCK1 | |
| SCHEMBL4298401 | 0.82 | SLC2A1 (0.50) | SLC2A1RPS6KA5AKT1RPS6KA1ROCK1 | |
| SCHEMBL4296943 | 0.81 | SLC2A1 (0.57) | SLC2A1RPS6KA5AKT1RPS6KA1ROCK1 | |
| SCHEMBL690731 | 0.80 | RPS6KA5 (0.63) | SLC2A1RPS6KA5AKT1RPS6KA1ROCK1 | |
| SCHEMBL4288391 | 0.79 | SLC2A1 (0.70) | SLC2A1RPS6KA5AKT1RPS6KA1ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227616-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION, A CORPORATION | 2009-09-10 | — | — | US | disclosed |
| EP-1948185-A2 | INHIBITORS OF AKT ACTIVITY | SmithKline Beecham Corporation (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007058852-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227616-A1 | INHIBITORS OF AKT ACTIVITY | PI4KB, PIK3CA, AKT2 | SLC2A1 3039/4885RPS6KA5 156/4885AKT1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.